<DOC>
	<DOCNO>NCT02200978</DOCNO>
	<brief_summary>Outcome acute promyelocytic leukemia ( APL ) greatly improve since introduction all-trans-retinoic acid ( ATRA ) . Treatment ATRA anthracycline-based chemotherapy ( ATRA + chemotherapy ) decrease relapse disease well early hemorrhagic death . Nowadays patient APL event-free survival ( EFS ) 80 % . However , remain subset patient disease relapse . Recently , randomize prospective study show addition ATO `` ATRA + chemotherapy '' treatment protocol significantly high EFS patient APL treat `` ATRA + chemotherapy '' protocol . The patient treat `` ATO + ATRA + chemotherapy '' five year EFS 89.2 % . Moreover , recent study show Indigo naturalis formula ( RIF ) , traditional Chinese medicine tetraarsenic tetrasulfide ( As4S4 ) , indirubin , tanshinone IIA major active ingredient , yield synergy treatment murine APL model vivo induction APL cell differentiation vitro . It 20 year since RIF use treat ALP China . Clinical study show agent effective APL . Compared ATO , RIF relatively inexpensive take orally , result reduce number hospital day treatment cost . However , report compare treatment outcomes `` ATO + ATRA + chemotherapy '' `` RIF + ATRA + chemotherapy '' protocol child APL far . For purpose , therefore , investigator go conduct multicenter randomize prospective study child APL .</brief_summary>
	<brief_title>A Study Improving Outcome Childhood Acute Promyeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy `` ATO/RIF + ATRA + less intensive chemotherapy '' protocol child acute promyelocytic leukemia ( APL ) . - Compare safetyï¼Œefficacy treatment cost `` RIF + ATRA + less intensive chemotherapy '' `` ATO + ATRA + less intensive chemotherapy '' protocol child APL . Determine ATO substitute RIF . OUTLINE : This multicenter randomize prospective study . PROJECTED ACCRUAL : A total 240 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients le 16 year old newly diagnose PMLRARa positive acute promyelocytic leukemia . Patients coma , convulsion paralysis due intracranial hemorrhage central nervous system leukemia diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>